Phaseline

Targets › SMN2

SMN2: drug programs, companies and trials

5 programs from 3 companies in 12 trials: 6 Phase 3, 2 Phase 4, 2 Phase 2, 2 Phase 1; Neurology; next expected readout Nov 2026.

Open in Phaseline: the race on SMN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheRisdiplam (RO7034067)
SMN2 pre-mRNA positive modulator
SMN2Phase 4Muscular Atrophy, Spinal; Spinal Muscular Atrophy (SMA)Nov 2026
BiogenNusinersen (BIIB058)
SMN2 pre-mRNA positive modulator
SMN2Phase 3Spinal Muscular Atrophy; Muscular Atrophy, SpinalSep 2027
BiogenSalanersen (BIIB115)
SMN2 splicing modulator that increases production of functional SMN protein
SMN2Phase 3Spinal Muscular Atrophy; Muscular Atrophy, Spinal; Healthy VolunteerJun 2028
Novartisonasemnogene abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy (SMA)Apr 2031
NovartisOnasemnogene Abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy Type IDec 2035

Conditions

Muscular Atrophy, Spinal (6) Spinal Muscular Atrophy (SMA) (2) Spinal Muscular Atrophy (2) Healthy Volunteer (1) Spinal Muscular Atrophy Type I (1)

Modalities

other (4), small molecule (1)

Companies

Biogen (2) Novartis (2) Roche (1)

Related targets

SMN1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.